| 3.25 0.03 (0.93%) | 03-09 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Guardion Health Sciences, Inc. (GHSI), along with its various affiliates, functions as a specialized healthcare enterprise operating within the United States. The company's operations are divided into two primary segments: Medical Foods and Nutraceuticals, and Medical Devices. Under its Medical Foods division, Guardion Health Sciences offers Lumega-Z, a therapeutic food designed to replenish and restore the eye's macular protective pigment. It also provides GlaucoCetin, a specialized medical food formulated to support and safeguard the mitochondrial function of optic nerve cells, and to improve ophthalmic artery blood flow in patients afflicted with glaucoma. In the Medical Devices sector, the company supplies MapcatSF, a device used to precisely measure macular pigment optical density. It also markets the CSV-1000, which conducts self-calibrated tests to ensure accurate luminance and contrast levels, and the CSV-2000, a digital system for standardized contrast sensitivity testing. Moreover, Guardion Health Sciences develops, manufactures, and distributes equipment and accessories for standardized vision screening under the VectorVision name, utilized by vision care professionals in clinical research, real-world diagnostic evaluations, and occupational vision assessments. Furthermore, the company is actively developing ImmuneSF, a new nutraceutical blend, and manages a comprehensive collection of nutritional supplement products marketed under its NutriGuard brand. Its medical food items are distributed directly to consumers via its online store, guardionhealth.com. Guardion Health Sciences, Inc. was established in 2009 and is headquartered in San Diego, California.
Thu, 24 Apr 2025
GHSI Stock Price, News & Analysis - Stock Titan
Fri, 04 Oct 2024
Guardion Health Sciences Announces Delisting and New Interim CEO - Yahoo Finance
Thu, 22 Aug 2024
GHSI stock soars to 52-week high, touches $10.99 - Investing.com
Wed, 21 Aug 2024
Guardion Health Sciences Declares Cash Dividend of $5.00 Per Share of Common Stock - GlobeNewswire
Tue, 13 Aug 2024
Alantra advises Guardion Health on strategic sale of Viactiv to KingdomWay Group - Alantra
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
OTC
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|